Get started

Community ideas

Dhani Services Ltd. Based on Rectangle Pattern Breakout 1. Pattern Analysis - Rectangle Pattern: - Timeframe: 2 Years - Description: The stock has been consolidating within a rectangle pattern, with a well-defined resistance at ₹75 and support at ₹40. This prolonged sideways movement indicates accumulation and a potential buildup for a significant move. - The breakout above ₹75 marks the end of the consolidation phase and the start of an upward trend, confirming a bullish breakout. 2. Volume Analysis - Volume Behavior: - During the consolidation phase, volume remained low, which is typical for a rectangle pattern. - A notable volume spike during the breakout, as seen recently, signifies increased market participation and validates the breakout. 3. Price Action Analysis - Resistance Levels: - ₹75: The previous resistance and breakout level. - ₹90–₹100: Immediate target zone based on historical price action. - Support Levels: - ₹60: Potential retest zone after the breakout. - ₹40: The lower boundary of the rectangle, serving as the final support. - Candlestick Behavior: - The breakout was marked by a strong bullish candlestick with a close near its high, indicating momentum. - Recent higher highs and higher lows further confirm bullish price action. 4. Validation of Bullish Signal - The breakout above ₹75 is supported by a clear volume spike, showing increased demand. - The long consolidation period adds reliability to the breakout, as prolonged patterns tend to yield stronger moves. 5. Target Setting - Rectangle Pattern Target: - Height of the rectangle = ₹75 - ₹40 = ₹35. - Target = ₹75 + ₹35 = ₹110. - Incremental Targets: - Target 1: ₹90 (+20% from ₹75). - Target 2: ₹110 (+46% from ₹75). 6. Entry and Stop Loss - Entry Levels: - Primary Entry: Above ₹75 after the breakout. - Pullback Entry: Near ₹60 if the stock retests the breakout level. - Stop Loss: - Place a stop loss at ₹60, below the potential pullback zone. 7. Trade Setup Summary - Entry Levels: - Above ₹75 for momentum traders. - Near ₹60 for a pullback entry. - Targets: - Target 1: ₹90 (+20%). - Target 2: ₹110 (+46%). - Stop Loss: ₹60. 8. Final Notes Dhani Services Ltd. has successfully broken out of a 2-year rectangle pattern, with strong volume confirming the breakout. The long-term consolidation suggests that the breakout has significant potential to drive the stock higher, making it an attractive opportunity for traders. Close monitoring of price action around ₹75 and ₹60 is recommended for entry and to manage risk effectively.
NSE:DHANILong
by Mr_Chartist_
7
SRM Trade ideaThere was dal in price after IPO. Then new uptrend started for some time it consolidated and moved on sideways trend. Now be new uptrend is likely to unfold as there are clear increased volumes and inspite of DOJI candle the volume increase in last trading session. So FVG created ; price may retrace till 280-290 We can buy some quantity at CMP 314; add some at filling of FVG. THE TARGETS CAN BE upto 340,360,400 Based on Fibonacci extensions. Di your own analysis also and watch the price action. Comment about it.
NSE:SRMLong
by TradeKings5586
3
HCLTECH shortHCL Technologies (HCLTECH) is exhibiting signs of a potential bearish trend reversal. A clear bearish divergence has formed between price and the Relative Strength Index (RSI), indicating weakening bullish momentum. Key Observations: 1. Bearish Divergence: Price has made higher highs, but the RSI has formed lower highs. This divergence suggests a potential bearish trend reversal. 2. Volume Weakness: Volume has been declining as the price has increased, indicating waning buying interest. 3. Broken RSI Support: The stock has broken below a key weekly RSI support level and has retested it, confirming the bearish bias. Trading Strategy: Short Entry: Consider shorting HCLTECH around the current price level or a slight pullback to the broken RSI support level. Stop-Loss: Place a stop-loss order at 1900 on a closing basis to limit potential losses. Profit Targets: Target 1: 1700 Target 2: 1540 Target 3: 1420
NSE:HCLTECHShort
by VaibhavG1910
2
Is this stock potential? How can we trade? HDFC AMC All of the major index and stocks are trading in bearish structure. Market is potentially discounted and we can look for some buy opportunities. Looking at HDFC AMC stocks, it is still trading in Bullish structure. For any buy setup we would wait for a Change of structure on lower timeframe , mostly on 15 mins. Look for MSs on 15min and then we can target the daily recent high as future targets. Trade safe. This is just for educational purposes.
NSE:HDFCAMCLong
by Trade_lyst
1
SUNPHARMA - BREAKOUT RETEST or END of 5th?SUNPHARMA - CMP 1747 It appears that a 5 wave impulse from Covid lows (312) has ended at 1960 Primary and internal counts are marked in the chart If it is too early to predict/expect a larger retracement of the entire move, lets take one step at a time and look for the price action from May'23 lows.. The 5 wave impulse from 922 to 1960. Even here, the 5 waves are complete and the price is falling/retracing. Chart is attached here for reference If we expect a minimum of 50% retracement of this 5 wave impulse, then we are looking at 1440 levels Worst case, if you look at breakout retest (for those with bullish bias), then a dip down to 1640 cant be ruled out Price is trading below the cloud and Super trend on Daily TF Price is trading below all key EMAs.. and 200 EMA is next, placed at 1650 levels. Definitely not a place to go long.. Daily close above 1800 would be the invalidation level I am not a SEBI registered Analyst. Views are personal and for educational purpose only. Please consult your Financial Advisor for any investment decisions.
NSE:SUNPHARMAShort
by Murthy_Santhosh
3
NIFTY50-pain in short term & reward in long term ....NIFTY50 : 23572.30 NIFTY is in Primary Bull cycle phase (on weekly charts) and in middle of Wave -3, which should take the NIFTY at levels of 33k-43K & finally 55K in next 2 years’ time frame . On immediate basis (on daily chart basis) chart structure suggest it has entered Intermediate level wave -4 correction. Nifty at its crucial support of 200 Simple Moving Average, and on the weak footing. If nifty doesn’t hold these levels, it will open the downside till 20420 levels . Chart structure suggest that still downside risk is open. The support levels are listed below 200 SMA placed @23542 S1- 22557; S2-21675; S3- 20420 Currently Nifty is in price correction mode which suggest it to last till Jan 25, and if followed by time corrections, than Fibonacci level suggest the these correction may last till another 2 quarters (Q1 FY25).
NSE:NIFTY
by DrPrashantVerma
7
DCAL - Potential C&H -Back in Profits. Buy above 215.DCAL is forming Cup & Handle Pattern. One can enter above 215 with target of 255/400/600/780, with Stop Loss of 171. Here's a summary of the key points for investors from Dishman Carbogen Amcis Limited's (DCAL) presentation for Q2 FY25: Financial Highlights 1. Revenue Growth: Net revenue for Q2 FY25 increased by 34.5% YoY to ₹7,890 million, driven by a boost in commercial sales, particularly in the CRAMS (Contract Research and Manufacturing Services) segment in Switzerland and India. 2. Profitability: EBITDA rose significantly to ₹1,485 million with a margin increase from 10.8% in Q2 FY24 to 18.8% in Q2 FY25, due to higher volumes and improved operating margins. 3. Cash Profit: Cash profit for Q2 FY25 stood at ₹1,055 million, almost doubling YoY. 4. Net Debt: The company reported a net debt of CHF 173 million as of September 2024. 5. Capex: H1 FY25 capital expenditure reached approximately USD 15.9 million. Operational Highlights 1. Revenue Mix: - CRAMS: Major contributor with 84% of total revenue. Sales grew 51.7% YoY, fueled by increased commercial sales. - NCE APIs & Intermediates: 6.2% share, with a 36.9% increase in revenue due to growth at the Bavla site in India. - Cholesterol & Vitamin D Analogues: Decline in sales by 35.7% due to lower margin realization in Cholesterol SF. - Quats & Generics: Decline due to reduced demand in the agrochemical sector. 2. Capacity Utilization: Focused on improving capacity utilization by targeting small to mid-sized global biotech companies and expanding in new geographies. Strategic Insights 1. Global Presence: Operations span Switzerland, the UK, France, Netherlands, India, and China, with 28 R&D labs and multi-purpose facilities. 2. Oncology Focus: Oncology, a high-growth therapeutic area, is a priority, with several late-phase oncology molecules in the pipeline. 3. HIPO Facility: The Bavla site in India houses Asia's largest high-potency API (HIPO) facility, positioning DCAL well for growth in oncology. Industry Overview - Specialty Medicines Growth: Specialty medicines, which include high-potency oncology drugs, are projected to grow significantly, with an expected 43% share in global pharma spending by 2028. - Oncology Market: Oncology is projected to grow at a CAGR of 14-17% through 2028, driven by new treatments and demand for potent drugs. Investment Considerations 2. ⁠1. Strong Revenue and Margin Growth: Consistent revenue growth with enhanced EBITDA margins, indicating improved operational efficiency. 2. Global Expansion & Diversification: Expanding into new geographies and targeting small/mid-size biotech clients mitigates risk and enhances revenue stability. 3. Oncology Focus and HIPO Facility: The HIPO capabilities in India align with the high-growth oncology sector, suggesting long-term growth potential in specialty pharma.
NSE:DCALLong
by jain_geetesh
1
Reliance Inds cmp 1267.60 by Weekly Chart viewReliance Inds cmp 1267.60 by Weekly Chart view - Stock has formed Bearish Rounding Bottom - Support Zone seen at 1050 to 1100 Price Band - Support Zone 1250 to 1300 Price Band turning into Resistance Zone - Stock might probably show more downside by the Technical Chart setup - Weekly Basis : Support at 1195 > 1100 > 995 with Resistance at 1360 > 1445 >1535 > ATH 1608.80 - Stock Price gone well below the crossover of both the Falling Resistance Trendline and also the Rising Support Trendline been broken down
NSE:RELIANCE
by PIYUSHCHAVDA
3